What question did this study set out to answer?

The study aims to evaluate how muscle health is assessed in GLP-1-based treatments for obesity, beyond just focusing on lean mass.

March 13, 2026Diabetes Obesity and Metabolism0 citations

View Full Paper

Rethinking Muscle Health Assessment in GLP ‐1–Based Therapies for Obesity: Beyond Lean Mass

MJMojca Jensterle AJAndrej Janež

Key Points

The study aims to evaluate how muscle health is assessed in GLP-1-based treatments for obesity, beyond just focusing on lean mass.
Analysis of current muscle health assessment techniques.
Review of GLP-1 therapy effectiveness in obesity management.
Discussion of additional factors impacting muscle health.
Current assessments may overlook critical aspects of muscle health.
A comprehensive approach is necessary for better treatment outcomes.
Beyond lean mass, factors like muscle function and quality are crucial.

Abstract

M.J. reports receiving lecture honoraria from Novo Nordisk, Eli Lilly, Pfeizer, Amgen, AstraZeneca, Novartis and Sanofi and being an advisory board member of Novo Nordisk, Eli Lilly, Amgen and Pfeizer. A.J. has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Abbott, Novo Nordisk, Medtronic, and Sanofi. The data that support the findings of this study are available from the corresponding author upon reasonable request. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70649.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Jensterle et al. (Tue,) studied this question.

synapsesocial.com/papers/69b3aad702a1e69014ccb852 https://doi.org/https://doi.org/10.1111/dom.70649

AI से पूछें

Bookmark

View Full Paper